Aptose Biosciences Stock News

SAN DIEGO and TORONTO, March 08, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase inh

SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the und

SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO , TSX: APS ), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will present and host one-on-one meetings at Oppenheimer''s 32 nd Annual Healthcare Conference: Aptose Presentation - Oppenheimer''s 32nd Annual Healthcare Conference Date: Tuesday, March 15, 2022 Time: 10:00 … Full story available on Benzinga.com

SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the under

Aptose Biosciences Inc (APTO) shares closed today 12.6% higher than it did at the end of yesterday. The stock is currently up 12.6% year-to-date, down 65.3% over the past 12 months, and up 12.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $1.55 and as low as $1.30 this week.Shares closed 78.9% below its 52-week high and 40.7% above its 52-week low.Trading volume this week was 3.6% higher than the 10-day average and 56.7% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 115.4% The company's stock price performance over the past 12 months lags the peer average by -4010.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

— H.C. Wainwright BIOCONNECT Virtual Conference —

-- Clinical development of the MYC repressor APTO-253 will be discontinued -- -- Company will focus on advancing kinome inhibitor pipeline --

Aptose Biosciences Inc (NASDAQ: APTO) will discontinue further clinical development of APTO-253 in hematologic malignancies and solid tumors.  The decision follows the prioritization of the Compan

Aptose Biosciences (TSX:APS)(NASDAQ:APTO) recovered 17% after losing 45% this week from results of its drug trial gave investors a wait-and-see report. The post Aptose Biosciences Climbs 17% to Reclaim Some Losses appeared first on The Motley Fool Canada .

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) CEO William G. Rice bought 17,822 shares of Aptose Biosciences stock in a transaction that occurred on Wednesday, December 15th. The stock was bought at an average price of $1.12 per share, with a total value of $19,960.64. The acquisition was disclosed in a legal filing with the SEC, which []

HC Wainwright reissued their buy rating on shares of Aptose Biosciences (TSE:APS) (NASDAQ:APTO) in a report issued on Tuesday, TipRanks reports. The brokerage currently has a C$14.00 price objective on the biotechnology companys stock. Separately, Cantor Fitzgerald reaffirmed an overweight rating on shares of Aptose Biosciences in a research report on Wednesday, November 17th. TSE:APS []

Brokerages expect Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) to report earnings of ($0.18) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Aptose Biosciences earnings, with the lowest EPS estimate coming in at ($0.20) and the highest estimate coming in at ($0.16). Aptose Biosciences reported earnings per share of []